CA1115698A - Selective hydrogenation products of c-076 compounds and derivatives thereof - Google Patents

Selective hydrogenation products of c-076 compounds and derivatives thereof

Info

Publication number
CA1115698A
CA1115698A CA312,880A CA312880A CA1115698A CA 1115698 A CA1115698 A CA 1115698A CA 312880 A CA312880 A CA 312880A CA 1115698 A CA1115698 A CA 1115698A
Authority
CA
Canada
Prior art keywords
dihydro
bla
ala
oleandrosyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA312,880A
Other languages
French (fr)
Inventor
John C. Chabala
Michael H. Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to CA312,880A priority Critical patent/CA1115698A/en
Application granted granted Critical
Publication of CA1115698A publication Critical patent/CA1115698A/en
Expired legal-status Critical Current

Links

Abstract

ABSTRACT OF THE DISCLOSURE
Derivatives of C-076 are described in which the C-076 molecule, as series of macrolides, has a specific unsaturation, at the 22,23-position, catalytically reduced. Further reaction of the reduced C-076 compounds are also possible. The compounds thus produced have profound anthelmintic, insecticidal,ectoparasiticidal and acaracidal activity. Compositions containing the described C-076 derivatives as the active ingredient thereof are also disclosed.

Description

l~S6~8 TITLE OF THE INVENTION
Selective Hydrogenation Products of C-076 Compounds and Derivatives Thereof BACKGROVND OF THE INVENTION
The term C-076 is used to describe a series of compounds isolated from the fermentation broth of a C-076 producting strain of Streptomyces avermitilis.
The morphological characteristics of the culture are B completely descr~ibe/d6in copending ~A5.application 10 Serial Number 7,~,G01. The C-076 compounds are a series of macrolides, each of which is substituted thereon at the 13-position with a 4-(a-L-oleandrosyl)-a-L-oleandrose group. The l-series of C-076 compounds also has a 22,23-double bond, as well as several 15 other double bonds. The selective reduction of the 22,23-double bond, without affecting the remaining double bonds is the subject matter of the instant application. The C-076 compounds and the instant derivatives thereof have a very high degree of 20 anthelmintic and antiparasitic activity.

~1156~8
-2- 16112 IA
SUMMARY OF THE INVENTION
The C-076 series of compounds have the following structure:
Rl ~ ~ ~2 CH3 ~
0~
,~, wherein R is the 4'-(~-L-oleandrosyl)-a-L-oleandrose 5 group of the structure:

HO - ~ O -and wherein the broken line indicates a single or a double bond; Rl is hydroxy and is present only when said broken line indicates a single bond;
R2 is iso-propyl or sec-butyl; and R3 is methoxy or hydroxy.
There are eight different C-076 compounds and they are given the designations Ala, Alb, A2a, A2b, Bla, Blb, B2a, B2b based upon the structure of the individual compounds.

~5~8
-3- 16112 IA
In the foregoing structural formula, the individual C-076 compounds are as set forth below.

Rl R2 R3 Ala Double bond sec-butyl -OCH3 5 Alb Double bond lso-propyl -OCH3 A2a -OH sec-butyl -OCH3 A2b -OH lso-propyl -OCH3 Bla Double bond s -butyl -OH
Blb Double bond iso-propyl -OH
10 B2a -OH sec-butyl -OH
B2b -OH lso-propyl -OH

The C-076 compounds with the 22,23-unsatura-tions are identified as the "l-series" and it is only these compounds which are reduced to prepare the 15 instant derivatives. Either before or after the reduction of the 22,23-double bond further reactions may be carried out in which one or both of the a-L-oleandrose moieties are removed, or in which one or more of the available hydroxy groups are acylated.
Thus, the compounds of the instant invention have the following structural formula:

3 ~ CH3 -O 1 ~ ~ R

CH3 ~

~ CH3 -~115698
-4- 16112 IA
wherein Rl is iso-propyl or sec-butyl;
R2 is methoxy, hydroxy or loweralkanoyloxy;
R3 is hydrogen; loweralkanoyl; a-L-
5 oleandrosyl; 4'-loweralkanoyl-~-L-oleandrosyl; 4'-(a-L-oleandrosyl)-~-L-oleandrosyl; 4"-loweralkanoyl-4'-(a-L-oleandrosyl)-a-L-oleandrosyl.
In the instant invention, the term "loweralkanoyl" is intended to include those alkanoyl 10 groups of from 2 to 6 carbon atoms such as acetyl, propionyl, butyryl, pivaloyl and the like.
Preferred compounds of the instant invention are realized in the above structural formula when:
Rl is lso-propyl or sec-butyl;
R2 is methoxy or hydroxy; and ~ 3 is hydrogen ~-L-oleandrosyl or 4'-(a-L-oleandrosyl)-~-L-oleandrosyl.
Additional preferred compounds are realized 20 when the "loweralkanoyl" group of R3 is acetyl in the disaccharide, monosaccharide and aglycone compounds.
As is readily apparent from an analysis of the structure of the C-076 starting materials, there are five unsaturations in the l-series of compounds.
25 An object of the instant invention is to reduce the 22,23-double bond while not affecting the remaining four unsaturations or any other functional group present on the molecule. It is necessary to select a specific catalyst for the hydrogenation, one that 30 will selectively hydrogenate the least hindered from among a series of unsaturations. The 1~15698 preferred catalyst for such a selective hydrogenation procedure is one having the formula:

[(R4)3P]3RhX

wherein R4 is loweralkyl/ phenyl, or loweralkyl 5 substituted phenyl and X is a halogen.
In the preferred catalyst R4 is phenyl and X
is chlorinel that is the compound tris(triphenyl-phosphine~-rhodium (I) chloridel which is also known as Wilkinson's homogeneous catalyst.
The reaction is carried out using a catalytic amount of the catalyst. The amount of catalyst is not critical and from 0.05 to 0.5 moles of the catalyst for each mole of starting material have been successfully employed. Mslar ratios in the range of 15 0.25 t9 0.40 are preferred.
The hydrogenation is carried out in a hydrogen atmosphere which may be either at atmospheric pressure or up to about 4 atmospheres pressure in a standard laboratory hydrogenation apparatus. A
20 solvent is normally employed to dissolve both the starting materials and the catalyst. ~referred solvents are hydrocarbon solvents such as benzenel toluenel petroleum ether and other alkane hydrocarbons.
The reaction is complete when the calculated amount 25 of hydrogen has been taken up by the reaction. This will generally require from about 1 to 48 hours.
The reaction may be carried out at from room temperature to about 75C, however, room temperature is preferred. The hydrogenation products are isolated lil5698
-6- 16112 IA
and purified by techniques known to those skilled in the art.
Other reactions may be carried out on the C-076 starting materials or on the hydrogenated 5 products to prepar~ the compounds of this invention.
While it is possible to complete all of the other reactions on the C-076 starting material and have the hydrogenation step as the final reaction, it is preferred to carry out the hydrogenation step first.
Because the 22,23-double bond is somewhat susceptible to nucleophilic addition, reaction conditions for removing the sugar groups or acylating the hydroxy groups must be carefully controlled if the 22,23-double bond is present. If the 22,23-double bond is 15 hydrogenated first, the subsequent sugar removal and acylation is rendered more facile.
Thus, the additional reactions which may be carried out to prepare the compounds of this invention are the selective removal of one or both of 20 the a-L-oleandrosyl moieties or the selective acylation of the susceptible hydroxy groups.
The reaction conditions which are generally applicable to the preparation of both the monosaccharide and aglycone involve dissolving the C-076 compound or 25 the hydrogenated C-076 compound in an aqueous acidic non-nucleophilic organic solvent, miscible with water, preferably dioxane, tetrohydrofuran, dimethoxyethane, dimethyl formamide, b -2-methoxyethyl ether, and the like, in which the water concentration is from 30 0.1 to 20% by volume. Concentrated acid is added to the aqueous organic solvent to the extent of 0.01 to ~1~5698 -7_ 16112 IA
10% by volume. The reaction mixture is generally stirred at about 20-40C, preferably at room temperature, for from 6 to 24 hours. The lower concentrations of acid, from about 0.01 to 0.1%
5 will predominately produce the monosaccharide under the above reaction conditions. Higher acid concentrations, from about 1 to 10% will predominantly produce the aglycone under the above reaction conditions.
Intermediate acid concentrations will generally 10 produce mixtures of monosaccharide and aglycone.
The products are isolated, and mixtures are separated by techniques such as column, thir layer preparative and high pressure liquid chromatography, and other known techniques.
The acids which may be employed in the above process include mineral acids and organic acids such as sulfuric, hydrohalic, phosphoric, trifluoro-acetic, trifluoro methane sulfonic and the like.
The hydrohalic acids are preferably hydrochloric or 20 hydrobromic. The preferred acid in the above process is sulfuric acid.
A further procedure for the preparation of the monosaccharide or aglycone of the C-076 compounds or of the hydrogenated C-076 compounds utilizes a 25 different solvent system for the monosaccharide and the aglycone. The procedure for the preparation of the monosaccharide uses 1% acid by volume in isopropanol at from 20-40C, preferably room temperature, for from 6 to 24 hours. For the 30 preparation of the aglycone, 1% acid, by volume, in methanol under the foregoing reaction conditions has been found to be appropriate.

A ~

When this procedure is employed on the starting material (the compounds with the 22,23-double bond) there is a possibility of nucleophilic addition to the double bond. If such occurs, chromatographic 5 purification will remove the by-product in order to allow for further reactions.
The acids listed above are appropriate for this process, and again sulfuric acid is the preferred acid.
The above described compounds are isolated from the reaction mixture and mixtures of compounds are separated using techniques known to those skilled in this art, and in particular the chromatographic techniques described above.
The acylated compounds are prepared using acylation techniques in which the reaction conditions will vary, depending upon the reactivity of the hydroxy group being acylated. Where there is more than one hydroxy group to be acylated, different reaction 20conditions are employed to minimize the formation of mixtures.
The acylation reagents employed are generally the halide, preferably the chloride, of the above loweralkanoyl groups. That is the loweralkanoyl 25halide reagent is generally employed.
In addition, the acylation reagent could be in the form of the anhydride or of the halo formate.
In the case of reactions carried out with the halide reagents, it is often advantageous to include 30in the reaction mixture a basic compound capable of ~115698 reacting with and neutralizing the hydrogen halide which is liberated during the course of the reaction.
Tertiary amines are preferred such as triethylamine, pyridine, dimethylamino pyridine, diisopropyl 5 ethylamine and the like. The basic compound is required in equimolar amounts relative to the numbered moles of hydrogen halide being liberated, however excess amounts, even using the basic compound as a solvent, are not detrimental.
In the case of the Al compounds of C-076, or of the hydrogenated C-076 Al compounds there is only a single hydroxy group, 4" hydroxy, which may be acylated. The formation of the monosaccharide or the aglycone still leaves only a single hydroxy group 15 which may be acylated, that is the 4' or 13 hydroxy group.
In the case of the 4", 4' and 13 hydroxy groups of C-076 Al compounds, the acylating reagent is dissolved in a suitable solvent, pyridine is preferred, 20 and the acylating reagent added. The reaction is maintained at from 0C to room temperature for from 4 to 24 hours. The product is isolated using known techniques.
The Bl compounds have 2 available hydroxy 25 groups: at the 4"(4' or 13) and the 5-positions.
However, the two hydroxy groups have similar reactivities. When the reaction of the acylating agent in pyridine is carried out at about room temperature for from 4 to 24 hours, the diacyl 30 compound is recovered. When the reaction is carried out at 0C a mixture of the 4"(4' or 13) and 5 monoacyl compounds are recovered. To recover individual compounds, the mixture is placed on a chromatographic column or a preparative layer chromatographic plate of ~15698 alumina or silica gel and the individual compounds are readily isolated. In addition, techniques such as high pressure liquid chromatography may be employed to separate mixtures of acylated compounds.
The acyl compounds thus prepared are isolated from the reaction mixture using techniques ~nown to those skilled in this art.
The novel compounds of this invention have significant parasiticidal activity as anthelmintics, 10 ectoparasiticides, insecticides and acaricides, in human and animal health and in agriculture.
The disease or group of diseases described generally as helminthiasis is due to infection of an animal host with parasitic worms known as helminths.
15 Helminthiasis is a prevalent and serious economic problem in domesticated animals such as swine, sheep, horses, cattle, goats, dogs, cats and poultry. Among the helminths, the group of worms described as nematodes causes widespread and often times serious infection in 20 various species of animals. The most common genera of nematodes infecting the animals referred to above are Haemonchus, Trichostrongylus, Ostertagia, Nematodirus, Cooperia, Ascaris, Bunostomum, Oesophagostomum, -Chabertia, Trichuris, Strongylus, Trichonema, 25 Dictyocaulus, Capillaria, Heterakis, Toxocara, Ascaridia, Oxyuris, Ancylostoma, Uncinaria, Toxascaris and Parascaris. Certain of these, such as Nematodirus, Cooperia, and Oesphagostomum attack -primarily the intestinal tract while others, such 30 as Haemonchus and Ostertagia, are more prevalent ~15698 in the stomach while still others such as Dictyocaulus are found in the lungs. Still other parasites may be located in other tissues and organs of the body such as the heart and blood vessels, 5 subcutaneous and lymphatic tissue and the like.
The parasitic infections known as helminthiases lead to anemia, malnutrition, weakness, weight loss, severe damage to the walls of the intestinal tract and other tissues and organs and, if left untreated, 10 may result in death of the infected host. The hydrogenated C-076 compounds of this invention have unexpectedly high activity against these parasites, and in addition are also active against Dirofilaria in dogs, Nematospiroides, Syphacia, Aspiculuris 15 in rodents, arthropod ectoparasites of animals and birds such as ticks, mites, lice, fleas, blowfly, in sheep Lucilia sp., biting insects and such migrating diperous larvae as Hypoderma sp. cattle, Gastrophilus in horses, and Cuterebra sp. in rodents.
The instant compounds are also useful against parasites which infect humans. The most common genera of parasites of the gastro-intestinal tract of man are Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Trichuris, and Enterobius.
25 Other medically important genera of parasites which are found in the blood or other tissues and organs outside the gastrointestinal tract are the filiarial worms such as Wuchereria, Brugia, Onchocerca and Loa, Dracunculus and extra intestinal stages of the 30 intestinal worms Strongyloides and Trichinella. The compounds are also of value against arthropods ~15698 parasitizing man, biting insects and other dipterous pests causing annoyance to man.
The compounds are also active against household pests such as the cockroach, Blatella sp., 5 clothes moth, Tineola sp., carpet beetle, Attagenus sp., and the housefly Musca domestica.
The compounds are also useful against insect pests of stored grains such as Tribolium sp., Tenebrio s and of agricultural plants such as 10 spider mites, (Tetranychus sp.), aphids, (Acyrthiosiphon sp.); against migratory orthopterans such as locusts and immature stages of insects living on plant tissue. The compounds are useful as a nematocide for the control of soil nematodes and 15 plant parasites such as Meloidogyne spp. which may be of importance in agriculture.
These compounds may be administered orally in a unit dosage form such as a capsule, bolus or tablet, or as a liquid drench where used as an anthelmintic in 20 mammals. The drench is normally a solution, suspension or dispersion of the active ingredient usually in water together with a suspending agent such as bentonite and a wetting agent or like excipient. Generally, the drenches also contain an antifoaming agent. Drench 25 formulations generally contains from about 0.001 to 0.5%
by weight of the active compound. Preferred drench formulations may contain from 0.01 to 0.1% by weight.
The capsules and boluses comprise the active ingredient admixed with a carrier vehicle such as starch, talc, 11i56~8 magnesium stearate, or di-calcium phosphate.
Where it is desired to administer the C-076 derivatives in a dry, solid unit dosage form, capsules, boluses or tablets containing the desired amount of 5 active compound usually are employed. These dosage forms are prepared by intimately and uniformly mixing the active ingredient with suitable finely divided diluents, fillers, disintegrating agents and/or binders such as starch, lactose, talc, magnesium stearate, 10 vegetable gums and the like. Such unit dosage formulations may be varied widely with respect to their total weight and content of the antiparasitic agent depending upon factors such as the type of host animal to be treated, the severity and type of 15 infection and the weight of the host.
When the active compound is to be administered via an animal feedstuff, it is intimately dispersed in the feed or used as a top dressing or in the form of pellets which may then be added to the finished feed 20or optionally fed separately. Alternatively, the antiparasitic compounds of our invention may be administered to animals parenterally, for example, by intraruminal, intramuscular, intratracheal, or subcutaneous injection in which event the active 25ingredient is dissolved or dispersed in a liquid carrier vehicle. For parenteral administration, the active material is suitably admixed with an acceptable vehicle, preferably of the vegetable oil variety such as peanut oil, cotton seed oil and the like. Other parenteral _ "

11~5698 vehicles such as organic preparation using solketal, glycerol formal, and aqueous parenteral formulations are also used. The active monosaccharide or aglycone C-076 compound or compounds are dissolved or suspended 5 in the parenteral formulation for administration; such formulations generally contain from 0.005 to 5% by weight of the active compound.
Although the antiparasitic agents of this invention find their primary use in the treatment and/or 10 prevention of helminthiasis, they are also useful in the prevention and treatment of diseases caused by other parasites, for example, arthropod parasites such as ticks, lice, fleas, mites and other biting insects in domesticated animals and poultry. They are also 15 effective in treatment of parasitic diseases that occur in other animals including humans. The optimum amount to be employed for best results will, of course, depend upon the particular compound employed, the species of animal to be treated and the type and 20 severity of parasitic infection or infestation.
Generally good results are obtained with our novel compounls by the oral administration of from about 0.001 to 10 mg. per kg. of animal body weight, such total dose being given at one time or in divided doses 25 over a relatively short period of time such as 1-5 days. With the preferred compounds of the invention, excellent control of such parasites is obtained in animals by administering from about 0.025 to 0.5 mg.
per kg. of body weight in a single dose. Repeat 30 treatments are given as required to combat re-infections 1~5~8 and are dependent upon the species of parasite and the husbandry techniques being employed. The techniques for administering these materials to animals are known to those skilled in the veterinary field.
When the compounds described herein are administered as a component of the feed of the animals, or dissolved or suspended in the drinking water, compositions are provided in which the active compound or compounds are intimately dispersed in an inert 10 carrier or diluent. By inert carrier is meant one that will not react with the antiparasitic agent and one that may be administered safely to animals. Preferably, a carrier for feed administration is one that is, or may be, an ingredient of the animal ration.
Suitable compositions include feed premixes or supplements in which the active ingredient is present in relatively large amounts and which are suitable for direct feeding to the animal or for addition to the feed either directly or after an intermediate dilution 20 or blending step. Typical carriers or diluents suitable for such compositions include, for example, distillers' dried grains, corn meal, citrus meal, fermentation residues, ground oyster shells, wheat shorts, molasses solubles, corn cob meal, edible bean mill feed, soya 25 grits, crushed limestone and the like. The active hydrogenated C-076 compounds are intimately dispersed throughout the carrier by methods such as grinding, stirring, milling or tumbling. Compositions containing from about 0.005 to 2.0% by weight of the active 30 compound are particularly suitable as feed pxemixes.
Feed supplements, which are fed directly to the .,.

animal, contain from about 0.0002 to 0.3% by weight of the active compounds.
Such supplements are added to the animal feed in an amount to give the finished feed the 5 concentration of active compound desired for the treatment and control of parasitic diseases. Although the desired concentration of active compound will vary depending upon the factors previously mentioned as well as upon the particular C-076 derivative employed, lO the compounds of this invention are usually fed at concentrations of between 0.00001 to 0.002% in the feed in order to achieve the desired antiparasitic result.
In using the compounds of this invention, the 15 individual hydrogenated C-076 components may be prepared and used in that form. Alternatively, mixtures of two or more of the individual hydrogenated C-076 components may be used, as well as mixtures of the parent C-076 compounds other C-076 compound or other active compounds 20 not related to C-076 and the compounds of this invention.
In the isolation of the C-076 compounds, which serve as starting materials for the instant processes, from the fermentation broth, the various C-076 compounds will be found to have been prepared in unequal amounts.
25 In particular an "a" series compound will be prepared in a higher proportion than the corresponding "b" series compound. The weight ratio of "a" series to the corresponding "b" series is about 75:25 to 99:1. The 29 differences between the "a" series and "b" series is constant throughout the C-076 compounds and consists of a sec-butyl group and an iso-propyl group respectively at 1~15698 the 25 position. This difference, of course, does not interfere with any of the instant reactions. In particular may not be necessary to separate the "b"
components from the related "a" component. Separation 5 of these closely related compounds is generally not practiced since the "b" compound is present only in a very small percent by weight, and the structural difference has negligible effect on the reaction processes and biological activities.
In particular it has been found that the starting materials for the compounds of this invention are very often prepared in a ratio of about 80% C-076 Bla or Ala and 20% C-076 Blb or Alb. Thus the preferred composition of this invention is one lS which contains about 80% of the "a" component and 20% of the "b" component.
The C-076 compounds of this invention are also useful in combatting agricultural pests that inflict damage upon crops while they are growing or 20 while in storage. The compounds are applied using known techniques as sprays, dusts, emulsions and the like, to the growing or stored crops to effect protection from such agricultural pests.
The following examples are provided in order 25 that this invention might be more fully understood;
they are not to be construed as limitative of the invention.
The hydrogenated C-076 derivatives prepared in the following examples are generally isolated as 30 amorphous solids and not as crystalline solids. They are thus characterized analytically using techniques such as mass spectrometry, nuclear magnetic resonance, and the like. Being amorphous, the compounds are not characterized by sharp melting points, however, the 35 chromatographic and analytical methods employed indicate that the compounds are pure.

lllS698 22,23-Dihydro C-076 Ala 51.0 Mg. of C-076 Ala and 14.4 mg. of tris (triphenylphosphine) rhodium (I) chloride are combined 5 in 3.5 ml. of benzene and hydrogenated for 20 hours at room temperature under atmospheric pressure. The crude reaction mixture is chromatographed on a preparative layer chromatography plate eluting twice with 10% tetrahydrofuran in chloroform. The product 10 is removed from the support using ethyl acetate which is evaporated to dryness and the residue analyzed with 300 MXz nuclear magnetic resonance and mass spectroscopy indicating the preparation of 22,23-dihydro C-0 76 Ala.

EXA~LE 2 ?2,23-Dihydro C-076 Bla The solution of 87. 3 mg. of C-076 Bla in 6 ml.
of benzene containing 25 mg. of tris (triphenylphos-phine rhodium (I) chloride is hydrogenated for 4 hours 20 at room temperature under 1 atmosphere of hydrogen pressure. Preparative layer chromatography on silica gel eluting with 20~ tetrahydrofuran in chloroform recovers starting material. The sample is rehydro-genated following the above conditions for 19 hours.
25 Preparative layer chromatography recovers 55 mg.
of 22,23-dihydro C-076 Bla which is identified by mass spectrometry and 300 MHz nuclear magnetic resonance.

11~5~i~8 22,23-Dihydro C-076 Bla A solution of 1.007 g. of C-076 Bla, 314 mg.
of tris (triphenylphosphine) rhodium (I) chloride and 5 33 ml. of benzene is hydrogenated for 21 hours at room temperature under 1 atmosphere of hydrogen pressure. The solvent is removed in vacuo and the residue dissolved in a l:l mixture of methylene chloride and ethyl acetate and filtered. The filtrate 10 is placed on a column of 60 g. of silica gel eluting with a 1:1 mixture of methylene chlorid and ethyl acetate taking 10 ml. fractions. Fractions 14-65 are combined and evaporated to dryness affording 1.118 g. of a solid material which is indicated by 15 high pressure liquid chromatography to be a 60/40 mixture of the hydrogenated product and starting material. The mixture is rehydrogenated in 55 ml.
of benzene adding 310 mg. of tris (triphenylphosphine) rhodium (I) chloride and stirring for 21 hours at 20 room temperature under 1 atmosphere of hydrogen pressure. The solvent is removed in vacuo and the residue chromatographed on 80 g. of silica gel using 40:60 mixture of ethyl acetate and methylene chloride as eluant. 10 Ml. fractions are taken and the product 25 appears in fractions 26-80. These fractions are combined and evaporated to dryness in vacuo affording a yellow oil. The oil is dissolved in benzene and lyophilized affording a pale yellow powder which is identified as 22,23-dihydro C-076 Bla by mass 30 spectrometry and 300 MHz nuclear magnetic resonance.
0.976 G. of product is obtained.

11~56~8 22,23-Dihydro C-076 Ala Monosaccharide ll.2 Mg. of 22,23-dihydro C-076 Ala is dissolved in 1.1 ml. of 1% sulfuric acid in isopro-5 panol and stirred for 20 hours at room temperature.
The reaction mixture is diluted with chloroform to a volume of about 5.0 ml. and washed with saturated aqueous sodium bicarbonate solution and sodium chloride solution. The organic layer is dried over 10 sodium sulfate and evaporated to dryness in vacuo affording an oil. The oil is placed on a silica gel preparative layer chromatography plate and eluted with 5% tetrahydrofuran in chloroform. The product is removed from the plate and lyophilized from 15 benzene affording 5.2 mg. of a white powder which is identified by 300 MHz nuclear magnetic resonance and mass spectrometry as 22,23-dihydro C-076 Ala monosaccharide.

20 22,23-Dihydro C-076 Ala Aglycone 10.1 Mg. of 22,23-dihydro C-076 Ala is stirred for 20 hours in 1.1 ml. of 1% sulfuric acid in methanol at room temperature. The reaction mixture is treated as in Example 4 affording an oil which is 25 purified by preparative layer chromatography on silica gel eluting with 5~ tetrahydrofuran in chloroform.
The product is removed from the chromatography plate and lyophilized from benzene affording 4.2 mg. of a white powder which 300 MHz nuclear magnetic resonance 30 and mass spectrometry indicate to be 22,23-dihydro C-076 Ala aglycone.

-, ~ . .....

1115~98 22,23-Dihydro C-076 Bla Monosaccharide 395 Mg. of 22,23-dihydro C-076 Bla is added to a stirred solution of 50 ml. of 1~ sulfuric acid 5 in isopropanol and the solution is stirred for 14 hours at room temperature. The reaction mixture is treated as in Example 4 affording 0.404 g. of a foam after lyophilization from benzene. The foam is chromatographed on 6 preparative layer silica gel 10 chromatography plates eluting twice with 4~ tetra-hydrofuran in chloroform. The monosaccharide with a Rf 0.15 is collected and washed from the silica gel with a total of 650 ml. of ethyl acetate. The combined washings are evaporated to dryness and the 15 residue lyophilized from benzene to afford 0.2038 g.
of 22,23-dihydro C-076 Bla monosaccharide which high pressure liquid chromatography indicates to be essentially pure.

2022,23-Dihydro C-076 Bla Aglycone 9.7 Mg. of 22,23-dihydro C-076 Bla is stirred overnight in 1 ml. of a 1% sulfuric acid in methanol solution. The reaction mixture is treated as in Example 4 and the solid material treated with 2spreparative layer chromatography on silica gel eluting with 10% tetrahydrofuran in chloroform. The oil recovered from the chromatography plate is lyophilized from benzene affording 4.7 mg. of a white powder which 300 MHz nuclear magnetic resonance and mass 30spectrometry indicate to be 22,23-dihydro C-076 Bla aglycone.

l~lS6~8 22,23-Dihydro C-076 Bla Aglycone 0.486 G. of 22,Z3-dihydro C-076 Bla is added to a stirred solution of S0 ml. of 1~ sulfuric 5 acid in methanol and the reaction mixture stirred for 13 hours at room temperature. The reaction mixture is diluted with 250 ml. of methylene chloride and washed with 50 ml. of saturated aqueous potassium bicarbonate and 50 ml. of water. The aqueous layer 10 is washed twice with 20 ml. portions of methylene chloride and the combined organic phases are dried with saturated brine and sodium sulfate and evaporated to dryness in vacuo affording 0.480 g. of a pale yellow foam. The foam is dissolved in 4 ml. of 15 methylene chloride and placed on 4 preparative layer chromatography silica gel plates and eluted 4 times with 4~ tetrahydrofuran and chloroform. The product is recovered from the silica gel plates affording an oily residue which is lyophilized from benzene affording 20 255.8 mg. of a white solid. Traces of methyl oleandroside are indicated to be present in the solid material. The white solid is then lyophilized again from benzene ar,d placed under high vacuum for 20 hours to remove the impurity affording 22,23-dihydro C-076 25 Bla aglycone.

~15698 4"-0-acetyl-22,23-Dihydro C-076 Ala 6.8 Mg. of 22,23-dihydro C-076 Ala is dissolved in 40 drops of anhydrous pyridine, chilled 5 to 0C and treated with 20 drops of acetic anhydride.
The reaction mixture is allowed to warm to room temperature and stirred overnight. The reaction mixture is diluted with 5 ml. of ether and 6 ml. of water and the layers separated. The aqueous phase 10 is washed twice with ether and the organic layers combined and back washed 3 times with water. The ether layer is dried over magnesium sulfate and evaporated to dryness in vacuo affording an oil. The oil is chromatographed on silica gel preparative 15 layer chromatography plates eluting with 5% tetra-hydrofuran in chloroform. The product is recovered from the plates and lyophilized from benzene affording 6.1 mg. of 4"-O-acetyl-22,23-dihydro C-076 Ala as determined by mass spectrometry at 300 MHz nuclear 20 magnetic resonance.

4"-O-acetyl-22,23-Dihydro C-076 Bla and 4",5-di-O-acetyl 22,23-Dihydro C-076 Bla 18.6 Mg. of 22,23-dihydro C-076 Bla is 25 dissolved in 63 drops (about 1 ml.) of dry pyridine and treated with 9 drops of acetic anhydride at 0C.
The reaction is stirred under nitrogen for 6 hours at 0C. The mixture is then quenched with 5 ml. of water and extracted 3 times with 3 ml. portions of 30 ether. The combined ether extracts are then washed 3 times with 3 ml. portions of water and dried ~1'15~98 over magnesium sulfate and evaporated to dryness in vacuo. The oil is chromatographed on preparative layer silica gel chromatography plates eluting twice with 5% tetrahydrofuran in chloroform affording 5 5.8 mg. of 4"-O-acetyl-22,23-dihydro C-076 Bla and 5.8 mg. of 4",5-di-O-acetyl-22,23-dihydro C-076 Bla after lyophilization from benzene. The structures are confirmed by 300 I~Hz nuclear magnetic resonance and mass spectrometry.

22,23-Dihydro C-076 Bla 39 G. of C-076 Bla is dissolved in 1540 ml.
of toluene and introduced into a 4 liter stirred autoclave. To this is added 3.9 g. of tris(triphenyl-15 phosphine)rhodium(I) chloride (Wilkinson's catalyst).A hydrogenation pressure of 40 psi. and a temperature of 40C is maintained with stirring for 4 1/2 hours.
At the end of this period liquid chromatographic analysis indicates 98% yield of dihydro C-076 Bla with 20 1.5% of tetrahydro C-076 Bla. The toluene is removed by evaporation in vacuo and the dark red gum is dissolved in ethanol at a rate of 4 ml. of ethanol per gram of product. Formamide at a rate of 10 ml. per gram of product is added and the solution heated on 25 the steam bath to 40-50 while added water at a rate of 2 ml. per gram of product. After crystallization commences the heat is removed and the solution allowed to cool slowly with stirring overnight. The solid is filtered off and washed with a mixture 3 parts water 30 and 1 part ethanol and dried in vacuo overnight. The solids are dissolved in 150 ml. of ethanol and warmed to 35-40C on the steam bath. Water, 150 ml. is added slowly with stirring. When solution is complete at 35C the heat is removed and the solution allowed to 35 cool slowly overnight. The crystals are removed by ~115698 filtration and washed with 50% aqueous ethanol and dried in vacuo overnight affording 32 . 55 g . of 22, 23-dihydro C-076 Bla with a m.p. of 155-157C.

Claims (19)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A process for the preparation of a C-O76 derivative having the formula:

the monosaccharide, aglycone or acetyl derivatives thereof, wherein in the formula:
R1 is iso-propyl or sec-butyl;
R2 is methoxy, hydroxy or loweralkanoyloxy; and R3 is hydrogen; loweralkanoyl; .alpha.-L-oleandrosyl;
4'-loweralkanoyl-.alpha.-L-oleandrosyl; 4'-(.alpha.-L-oleandrosyl-.alpha.-L-oleandrosyl; or 4"-loweralkanoyl-4'-(.alpha.-L-oleandrosyl)-.alpha.-L-oleandrosyl which comprises, (a) treating a C-O76 compound having the formula:

wherein R1, R2 and R3 are as previously defined, with hydrogen in the presence of a catalytic amount of a compound having the formula:
[(R4)3P]3RhX
wherein R4 is loweralkyl, phenyl or loweralkyl substi-tuted phenyl and X is a halogen, and (b) when the monosaccharide or aglycone thereof is desired, treating the 22,23-dihydro compound thus obtained with concentrated acid in an organic solvent and when the solvent is isopropanol re-covering the monosaccharide thereof and when the solvent is methanol recovering the aglycone thereof, and (c) when R2 is methoxy, acetylating said compound to provide the corresponding 4"-O-acetyl and when R2 is hydroxy, acetylating said compound to provide the corresponding 4",5-di-O-acetyl compound.
2. The process of Claim 1 in which R4 is phenyl and X is chlorine.
3. The process of Claim 1, wherein the starting C-O76 compound is the C-O76 Ala and there is obtained the 22,23-dihydro C-O76 Ala.
4. The process of Claim 1, wherein the starting C-O76 compound is the C-O76 Bla and there is obtained the 22,23-dihydro C-O76 Bla.
5. The process of Claim 3, wherein the 22,23-dihydro C-O76 Ala is treated with 1% sulfuric acid in isopropanol and recovering the 22,23-dihydro C-O76 Ala monosaccharide thus obtained.
6. The process of Claim 3, wherein the 22,23-dihydro C-O76 Ala is treated with 1% sulfuric acid in methanol and recovering the 22,23-dihydro C-O76 Ala aglycone thus obtained.
7. The process of Claim 4, wherein the 22,23-dihydro C-O76 Bla is treated with 1% sulfuric acid in isopropanol and recovering the 22,23-dihydro C-O76 Bla monosaccharide thus obtained.
8. The process of Claim 4, wherein the 22,23-dihydro C-O76 Bla is treated with 1% sulfuric acid in methanol and recovering the 22,23-dihydro C-O76 Bla aglycone thus obtained.
9. The process of Claim 3, wherein the 22,23-dihydro C-O76 Ala is treated with an acetylating agent and recovering the 4"-O-acetyl-22,23-dihydro C-O76 Ala thus obtained.
10. The process of Claim 4, wherein the 22,23-dihydro C-O76 Bla is treated with an acetylating agent and isolating the 4"-O-acetyl-22,23-dihydro C-O76 Bla and the 4",5-di-O-acetyl C-O76 Bla thus obtained.
11. The C-O76 derivative of the formula:

the monosaccharide, aglycone or acetyl derivatives thereof, wherein in the formula:
R1 is iso-propyl or sec-butyl;
R2 is methoxy, hydroxy or loweralkanoyloxy; and R3 is hydrogen; loweralkanoyl; .alpha.-L-oleandrosyl;
4'-loweralkanoyl-.alpha.-L-oleandrosyl; 4'-(.alpha.-L-oleandrosyl-.alpha.-L-oleandrosyl; or 4"-loweralkanoyl-4'-(.alpha.-L-oleandrosyl)-.alpha.-L-oleandrosyl, when prepared by the process defined in Claim 1 or by an obvious chemical equivalent.
12. The 22,23-dihydro C-O76 Ala, when prepared by the process defined in Claim 3 or by an obvious chemical equivalent.
13. The 22,23-dihydro C-O76 Bla, when prepared by the process defined in Claim 4 or by an obvious chemical equivalent.
14. The 22,23-dihydro C-O76 Ala monosaccharide, when prepared by the process defined in Claim 5 or by an obvious chemical equivalent.
15. The 22,23-dihydro C-O76 Ala aglycone, when prepared by the process defined in Claim 6 or by an obvious chemical equivalent.
16. The 22,23-dihydro C-O76 Bla monosaccharide, when prepared by the process defined in Claim 7 or by an obvious chemical equivalent.
17. The 22,23-dihydro C-O76 Bla aglycone, when prepared by the process defined in Claim 8 or by an obvious chemical equivalent.
18. The 4"-O-acetyl-22,23-dihydro C-O76 Ala, when prepared by the process defined in Claim 9 or by an obvious chemical equivalent.
19. The 4"-5-di-O-acetyl C-O76 Bla, when prepared by the process defined in Claim 10 or by an obvious chemical equivalent.
CA312,880A 1977-10-03 1978-10-06 Selective hydrogenation products of c-076 compounds and derivatives thereof Expired CA1115698A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA312,880A CA1115698A (en) 1977-10-03 1978-10-06 Selective hydrogenation products of c-076 compounds and derivatives thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83860377A 1977-10-03 1977-10-03
CA312,880A CA1115698A (en) 1977-10-03 1978-10-06 Selective hydrogenation products of c-076 compounds and derivatives thereof

Publications (1)

Publication Number Publication Date
CA1115698A true CA1115698A (en) 1982-01-05

Family

ID=25668785

Family Applications (1)

Application Number Title Priority Date Filing Date
CA312,880A Expired CA1115698A (en) 1977-10-03 1978-10-06 Selective hydrogenation products of c-076 compounds and derivatives thereof

Country Status (1)

Country Link
CA (1) CA1115698A (en)

Similar Documents

Publication Publication Date Title
EP0001689B1 (en) Selective hydrogenation products of c-076 compounds, derivatives thereof, their preparation and compositions for the treatment of parasitic infections containing the compounds
US4199569A (en) Selective hydrogenation products of C-076 compounds and derivatives thereof
US4171314A (en) 13-Halo and 13-deoxy C-076 compounds
US4289760A (en) 23-Keto derivatives of C-076 compounds
US4206205A (en) Monosaccharide and aglycone derivatives of C-076
US4201861A (en) Acyl derivatives of C-076 compounds
US4173571A (en) 13-Halo and 13-deoxy derivatives of C-076 compounds
US4457920A (en) 4a-Substituted avermectin compounds
AU609570B2 (en) Avermectin derivatives
US4579864A (en) Avermectin and milbemycin 13-keto, 13-imino and 13-amino derivatives
EP0074758B1 (en) 4a-substituted avermectin compounds, their production and antiparasitic use, and compositions containing them
EP0008184A1 (en) Alkyl derivatives of C-076 compounds, their preparation and their use as antiparasitic agents
IE47570B1 (en) Derivatives of c-076 compounds and their preparation
NZ229918A (en) Avermectin and milbemycin derivatives, parasiticides
AU614123B2 (en) Fluoroavermectin and fluoromilbemycin derivatives with antiparasitic and pesticidal properties
US4547491A (en) C-8A-Oxo-avermectin and milbemycin derivatives, pharmaceutical compositions and method of use
US4530921A (en) Avermectin epoxide derivatives and method of use
US4622313A (en) O-sulfate derivatives of avermectins and milbemycins having improved water solubility
NZ201594A (en) Derivatives of c-076 macrolides and pesticidal compositions
USRE32006E (en) 13-Halo and 13-deoxy C-076 compounds
US4581345A (en) Avermectin 8,9-cyclopropyl compounds, pharmaceutical composition and therapeutic methods of use
US5008250A (en) Avermectins with a cleaved furan ring and an 8a hydroxy group
CA1115698A (en) Selective hydrogenation products of c-076 compounds and derivatives thereof

Legal Events

Date Code Title Description
MKEX Expiry